GILD - Gilead Sciences, Inc.
81.50 -0.09 (-0.11%)
After hours: 6:57PM EDT
| Previous Close | 80.01 |
| Open | 81.53 |
| Bid | 81.50 x 100 |
| Ask | 81.69 x 300 |
| Day's Range | 80.52 - 82.47 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 13,616,132 |
| Avg. Volume | 9,327,947 |
| Market Cap | 106.55B |
| Beta | 0.90 |
| PE Ratio (TTM) | 8.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.59%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
Yahoo Finance Video•6 hours agoGilead shares up after FDA approves breakthrough cancer treatment
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
- TheStreet.com•2 hours ago
FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma
Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
- Investor's Business Daily•3 hours ago
Does Gilead Now Have A New Multi-Billion-Dollar Franchise?
Gilead jumped early Thursday after the FDA approved its CAR-T drug, dubbed Yescarta, to treat Non-Hodgkin lymphoma.
- Benzinga•7 hours ago
Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug
The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD )'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost ...
- InvestorPlace•7 hours ago
3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
- TheStreet.com•8 hours ago
Gilead Sciences Yescarta Drug Approved By FDA
Shares of Gilead Sciences rose 2% Thursday after the FDA approved its Yescarta lymphoma cancer therapy drug.
- Barrons.com•9 hours ago
Gilead: Congratulations…But You Still Overpaid for Kite
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
- TheStreet.com•9 hours ago
Gilead Stock Climbs as FDA Approves Lymphoma Cancer Therapy Drug Yescarta
The drug is anticipated to rake in $1.7 billion in worldwide sales in the next five years with a U.S. list price of $373,000.
- Zacks•10 hours ago
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
- TheStreet.com•10 hours ago
Gilead Sciences Poised to Make a Push Toward $100?
We have a new price target as GILD reacts to the FDA approving its cancer drug.
- Barrons.com•10 hours ago
Morning Movers: Gilead Gains, Nike Drops, Philip Morris Tumbles
The Dow looks set to drop around 100 points as U.S. markets look to follow international stocks lower this morning. S&P 500 futures have fallen 0.5% , while Dow Jones Industrial Average futures have declined ...
- TheStreet.com•11 hours ago
Catalonia, eBay, AmEx, Gilead - 5 Things You Must Know Before the Market Opens
U.S. stock futures are tumbling on Thursday, and European stocks are sinking after Spain's central government said it would assume control of the region of Catalonia.
- Investor's Business Daily•12 hours ago
S&P 500 Futures: These 5 Top Stocks Are Big Overnight Movers
Adobe Systems skyrocketed overnight on earnings guidance while eBay fell on its outlook. Gilead Sciences rallied on its big FDA win, also lifting Juno Therapeutics.
- Investopedia•13 hours ago
Gilead Shares Jump After FDA Approves Lymphoma Drug
Gilead Sciences' (GILD) $11.9 billion acquisition of Kite Pharma is paying off.
- The Wall Street Journal•19 hours ago
Gilead Gets FDA Approval for New Cancer Therapy
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
- Reuters•23 hours ago
U.S. FDA approves Gilead cancer gene therapy; price set at $373,000
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
- Reuters•yesterday
Gilead cancer immunotherapy wins U.S. approval with $373,000 price
A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer. Gilead said the price for the therapy with one-time administration would be $373,000. Gilead Sciences shares rose almost 4 percent to $83 in extended trading.
- Reuters•yesterday
FDA approves Gilead's Yescarta cancer immunotherapy
A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of ...
- Zacks•yesterday
Top Stock Reports for IBM, Celgene and Procter & Gamble
Top Stock Reports for IBM, Celgene and Procter & Gamble
- Market Realist•yesterday
Inside Gilead’s HBV Portfolio Performance in 1H17
In 1H17, Gilead Sciences' (GILD) Viread generated revenues of ~$560 million, compared with $559 in 1H16.
- Market Realist•yesterday
How Gilead’s HCV Drug Portfolio Is Positioned after 1H17
In 1H17, Gilead Sciences’ (GILD) Harvoni reported revenues of ~$2.75 billion, compared with $5.58 billion in 1H16.
Markit•yesterdaySee what the IHS Markit Score report has to say about Gilead Sciences Inc.
Gilead Sciences Inc NASDAQ/NGS:GILD
- CNBC Videos•yesterday
Gilead's newly approved cancer drug priced at $373,000
CNBC's Meg Tirrell reports on the FDA approving Gilead's cancer drug and what its priced at.
